mepolizumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
mepolizumab: clinical details
Prescribing considerations
- Confirm an appropriate eosinophilic phenotype and licensed indication; initiation should be by a clinician experienced in the relevant condition.
- Do not use for acute asthma or COPD exacerbations.
- Continue appropriate background treatment. Corticosteroid withdrawal must be gradual and supervised.
- Treat pre-existing helminth infection before starting. Consider interrupting mepolizumab if a new infection does not respond to antiparasitic treatment.
- Review clinical response and ongoing need for treatment periodically.
Contraindications and cautions
- Hypersensitivity to mepolizumab or any formulation excipient.
- Exercise caution where there is a history of systemic reactions to biological injections; immediate or delayed hypersensitivity can occur.
- Organ-threatening or life-threatening EGPA and life-threatening HES were not studied in the licensing trials.
Monitoring
- Disease control, exacerbations and continuing clinical benefit.
- Immediate and delayed systemic hypersensitivity or administration-related reactions.
- Helminth infection risk and response to treatment where relevant.
- Record product name and batch number to maintain biological-medicine traceability.
Clinical pharmacology
Mepolizumab is a humanised IgG1 kappa monoclonal antibody that neutralises interleukin-5. It is degraded by widely distributed proteolytic enzymes rather than hepatic cytochrome pathways and has a prolonged terminal half-life after subcutaneous administration.
Formulation and product differences
- The paediatric pre-filled syringe is a ready-to-use, single-use solution that may be administered by a trained caregiver when approved by the clinical team.
- The selected powder presentation is a single-use vial requiring aseptic reconstitution and healthcare-professional administration; eMC currently marks this presentation as discontinued.
- Both selected formulations are for subcutaneous use only and contain polysorbate 80, which can cause allergic reactions.
mepolizumab preparations and strengths
Injection
Route: Parenteral
Strengths: 40 mg, 100 mg
mepolizumab interactions
Formal interaction studies have not been performed, but clinically important pharmacokinetic interactions are considered unlikely because mepolizumab is not cleared through cytochrome P450 enzymes, transporters or protein-binding pathways. Patients should still tell their specialist about all medicines and supplements.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.